Ikena Oncology (formerly Kyn Therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed therapies for cancer patients, by understanding what drives their disease. Ikena leverages core capabilities in oncology drug discovery, translational sciences and clinical development to build a next generation product pipeline across distinct molecular targets and biologic pathways that address a broad range of cancers. Ikena went public in March 2021 (NASDAQ: IKNA).
| Headquarters | Boston, MA |
| Website | www.ikenaoncology.com |
| Pipeline | Clinical |
| @IkenaOncology | |
| Partner | Bristol-Myers Squibb |